business

Chinese inhibitor drug candidate becomes first to enter phase

Font size+Author:Stellar Sights news portalSource:sport2024-04-30 08:37:43I want to comment(0)

Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chines

Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.

SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.

The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.

The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.

Related articles
  • China's sci

    China's sci

    2024-04-30 08:37

  • Israel's Netanyahu says to increase pressure on Hamas

    Israel's Netanyahu says to increase pressure on Hamas

    2024-04-30 07:58

  • Horrifying moment car rams into ultra

    Horrifying moment car rams into ultra

    2024-04-30 07:25

  • Iowa lawmakers address immigration, religious freedom and taxes in 2024 session

    Iowa lawmakers address immigration, religious freedom and taxes in 2024 session

    2024-04-30 06:47

Netizen comments